Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
To demonstrate bioequivalence of a 2.5 mg saxagliptin/500 mg metformin (glucophage) immediate
release (IR) fixed dose combination (FDC) tablet to the 2.5 mg saxagliptin tablet and 500 mg
metformin IR tablet co-administered to healthy subjects in a fasted and in a fed state.